NCT01819935已完成不适用
Clinical Outcomes Among a National Veterans Affairs Methicillin Resistant Staphylococcus Aureus (MRSA) Pneumonia Cohort Treated With Linezolid Or Vancomycin
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 5,271
- 主要终点
- Time to 30-day Mortality
研究概览
简要总结
The purpose of this non-interventional, retrospective study of existing data is to evaluate clinical outcomes related to Methicillin-resistant Staphylococcus aureus hospital based pneumonia by treatment and among subpopulations.
详细描述
All patients meeting inclusion/exclusion criteria from inpatient database from 1/1/02-9/30/10.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •MRSA and pneumonia cases by ICD-9 code identification.
- •Diagnosis included during inpatient stay.
- •Treatment initiation in hospital.
排除标准
- •Death of discharge within 3 days of treatment initiation.
- •Exposure to other treatments with MRSA activity.
研究组 & 干预措施
linezolid (Zyvox)
干预措施: linezolid (Zyvox) (Drug)
Vancomycin
干预措施: vancomycin (Drug)
结局指标
主要结局
Time to 30-day Mortality
时间窗: Baseline (1 January 2001) up to 3559 Days (30 September 2010)
Time to death (all-cause mortality) occurring within 30 days of treatment initiation was reported. Mortality was assessed from admission vital status databases.
次要结局
- Time to Therapy Change(Baseline (1 January 2001) up to 3559 Days (30 September 2010))
- Time to Discharge From the Hospital(Baseline (1 January 2001) up to 3559 Days (30 September 2010))
- Time to Transfer Out From the Intensive Care Unit (ICU)(Baseline (1 January 2001) up to 3559 Days (30 September 2010))
- Time to Intubation(Baseline (1 January 2001) up to 3559 Days (30 September 2010))
- Time to 30-day Re-admission(Baseline (1 January 2001) up to 3559 Days (30 September 2010))
- Time to 30-day Methicillin-Resistant Staphylococcus Aureus (MRSA) Re-infection(Baseline (1 January 2001) up to 3559 Days (30 September 2010))
- Clinical Success(Baseline (1 January 2001) up to 3559 Days (30 September 2010))
研究者
相似试验
进行中（未招募）
不适用
A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the RussiaHR+HER2- Advanced Breast CancerNCT06148506Novartis Pharmaceuticals376
已完成
不适用
Retrospective Study of the Safety and Efficacy of Patients With RVO in Subjects Who Completed Parent Study CLS1003-201Macular EdemaRetinal Vein OcclusionNCT02956330Clearside Biomedical, Inc.20
已完成
不适用
Retrospective NIS to Evaluate the Patient Benefit of TESRetinitis PigmentosaNCT04983914Okuvision GmbH49
已完成
不适用
A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy With LEn/Dex in Greek Patients With R/R Multiple MyEloma and the Treatment PatterNs Following Progressive DiseaseRelapsed/Refractory Multiple MyelomaNCT02608515Genesis Pharma S.A.207
已完成
不适用
A National Study of Clinical Results After Emergency Operation for Perforated DiverticulitisPerforated DiverticulitisNCT03332550Sahlgrenska University Hospital, Sweden669